Skip to main content
. 2023 Dec 28;12:e83103. doi: 10.7554/eLife.83103

Figure 7. DFP does not normalize elevated TFR2 expression in MDS erythroblasts.

(A) Flow cytometry gating using TER119 and CD44 was used to delineate bone marrow erythroblasts. In these gated erythroblasts, we evaluate membrane TFR2 which is unchanged in MDS and DFP-treated MDS mice (n=6–7 mice/group) analyzed after 1 month of treatment. (B) TFR2 mRNA expression is borderline increased in sorted bone marrow ProE from MDS relative to WT mice and remains significantly elevated in DFP-treated MDS relative to WT mice (n=15–18 mice/group). When compared with sorted bone marrow ProE, TFR2 expression in sorted bone marrow BasoE (C), PolyE (D), and OrthoE (E) is significantly suppressed in MDS relative to WT mice and remains suppressed in PolyE and OrthoE from DFP-treated MDS mice (n=15–18 mice/group). (F) Western blot demonstrating TFR2 protein concentration in bone marrow erythroblasts is not different between WT, MDS, and DFP-treated MDS mice, quantified in (G) (n=3 mice/sample). *p<0.05 vs. WT; **p<0.01 vs. WT; Abbreviations: WT = wild type; MDS = myelodysplastic syndrome; DFP = deferiprone; TFR2 = transferrin receptor 2; ProE = pro-erythroblasts; BasoE = basophilic erythroblasts; PolyE = polychromatophilic erythroblasts; OrthoE = orthochromatophilic erythroblasts.

Figure 7—source data 1. Source data for flow analysis of cell surface transferrin receptor 2 (TFR2), TFR2 protein concentration in bone marrow erythroblast-enriched CD45 negative cells, and TFR2, in sorted bone marrow erythroblasts from wild type (WT), myelodysplastic syndrome(MDS), and DFP-treated MDS mice.
Figure 7—source data 2. Western blots with transferrin receptor 2 (TFR2) antibody staining relative to actin in bone marrow erythroblast enriched CD45 negative cells from wild type (WT), myelodysplastic syndrome (MDS), and DFP-treated MDS mice.

Figure 7.

Figure 7—figure supplement 1. Erythroblast TFR2 mRNA expression in WT, MDS, and DFP-treated MDS mice.

Figure 7—figure supplement 1.

No differences are observed in TFR2 mRNA expression in sorted BasoE (A), PolyE (B), and OrthoE (C) relative to ProE in WT, MDS, and DFP-treated MDS mice (n=5–15 mice/group). WT = wild type; MDS = myelodysplastic syndrome; DFP = deferiprone; TFR2 = transferrin receptor 2; ProE = pro-erythroblasts; BasoE = basophilic erythroblasts; PolyE = polychromatophilic erythroblasts; OrthoE = orthochromatophilic erythroblasts.
Figure 7—figure supplement 1—source data 1. Source data for transferrin receptor 2 (TFR2) in sorted bone marrow BasoE, PolyE, and OrthoE from wild type (WT), myelodysplastic syndrome (MDS), and DFP-treated MDS mice.
Figure 7—figure supplement 2. Erythroblast Scrib mRNA expression in WT, MDS, and DFP-treated MDS mice.

Figure 7—figure supplement 2.

No differences in Scrib mRNA expression are observed in sorted bone marrow ProE (A), BasoE (B), PolyE (C), and OrthoE (D) between WT, MDS, and DFP-treated MDS mice (n=15–18 mice/group). WT = wild type; MDS = myelodysplastic syndrome; DFP = deferiprone; ProE = pro-erythroblasts; BasoE = basophilic erythroblasts; PolyE = polychromatophilic erythroblasts; OrthoE = orthochromatophilic erythroblasts; Scrib = Scribble.
Figure 7—figure supplement 2—source data 1. Source data for Scribble (Scrib) in sorted bone marrow erythroblasts from wild type (WT), myelodysplastic syndrome (MDS), and DFP-treated MDS mice.